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The design of probes for the selective recognition of biopolymers (nucleic acids 
and proteins) is a fundamental task for studying, diagnosing, and treating diseases. 
Traditional methods utilize a single component (small molecule or oligonucleotide) that 
binds directly to the target biopolymer. However, many biopolymers are unable to be 
targeted with this approach. The overarching goal of this dissertation is to explore a 
new, binary approach for designing probes. The binary approach requires two 
components that cooperatively bind to the target, triggering a recognition event. The 
requisite binding of two-components allows the probes to have excellent selectivity and 
modularity.  
The binary approach was applied to design a new sensor, called operating 
cooperatively (OC) sensor, for recognition of nucleic acids, including selectively 
differentiating between single nucleotide polymorphisms (SNPs). An OC sensor 
contains two oligonucleotide probe strands, called O and C, each with two domains. 
The first domain contains a target recognition sequence, whereas the second domain is 
complementary to a molecular beacon (MB) probe. Binding of both probe strands to the 
fully matched analyte generates a full MB probe recognition site, allowing a MB to bind 
and report the presence of the target analyte. Importantly, we show that the OC sensor 
selectively discriminates between single nucleotide polymorphisms (SNPs) in DNA and 
RNA targets at room temperature, including those with stable secondary structures. 
Furthermore, the combinatorial use of OC sensors to create a DNA logic gate capable 
of analyzing DNA sequences of Mycobacterium tuberculosis is described.  
iv  
The binary approach was also applied to design covalent inhibitors for HIV-1 
reverse transcriptase (RT). In this application, two separate pre-reactive groups were 
attached to a natural RT ligand, deoxythymidine triphosphate (dTTP). Upon binding of 
both dTTP analogs in the RT active site, the pre-reactive groups are brought into the 
proper proximity and react with each other forming an intermediate that subsequently 
reacts with an amino acid side chain from the RT. This leads to covalent modification of 
RT, and inhibition of its DNA polymerase activity. This concept was tested in vitro using 
dTTP analogs containing pre-reactive groups derived from β-lactamase inhibitors 
clavulanic acid (CA) and sulbactam (SB). Importantly, our in vitro assays show that CA 
based inhibitors are more potent than zidovudine (AZT), a representative of the 
dominant class of RT inhibitors currently used in anti-HIV therapy. Furthermore, 
molecular dynamics simulations predict that complexes of RT with these analogs are 
stable, and point to possible reaction mechanisms. The inhibitors described in this work 
may serve as the basis for the development of the first covalent inhibitors for RT. 
Moreover, the pre-reactive groups used in this study can be used to design covalent 
inhibitors for other targets by attaching them to different ligands. Overall, the work 
presented herein establishes the binary approach as a straightforward way to develop 
new probes to selectively recognize nucleic acids and proteins.    
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CHAPTER 1: GENERAL INTRODUCTION  
 Proteins and nucleic acids are important biopolymers that perform a wide range 
of biological functions. The development of probes for the recognition of these 
biopolymers is a fundamental task for studying, diagnosing, and treating disease. 
Indeed, substantial efforts have been made to create new probes for this purpose. 
One of the most important characteristics of a probe is selectivity. Selectivity is the 
ability of a probe to differentiate its target from non-target molecules, and thus is a 
range from low (poor) to high (excellent). Traditional methods to develop probes have 
focused on developing a single ligand designed to selectively recognize the target 
(Figure 1). This recognition event may report the presence of the target or alter its 
function. Traditionally, selectivity is achieved by fine-tuning the interaction between the 
target and ligand. Adjusting chemical groups at different positions to promote high 
affinity for the target, thus hopefully reducing the likelihood of the probe binding to 
other biopolymers. Inherently, this limits the degree of selectivity achievable without 
compromising other important characteristics of the probe. Additionally, the vast 
majority of the human proteome has yet to be targeted with a probe for research or 
treatment purposes, perhaps to due limitations of the traditional strategy. Furthermore, 
a large portion of genomic diversity is due to single nucleotide polymorphism (SNPs), 
and design of probes for recognition of SNPs is still difficult. Thus, new approaches to 
design probes for recognition of both proteins and nucleic acids are needed.  
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Nature’s Approach 
There are many examples of natural biological systems with distinct and highly 
selective one-to-one complexes between two partner molecules: antibody-antigen, 
receptor-ligand, and kinase-substrate. Mimicking this approach to design probes for 
recognition of nucleic acids and proteins has been successful. However, nature uses 
more than just the one-to-one approach. Often, recognition events only occur when 
multiple partners bind to each other. One of the classical examples is the excellent 
selectivity of sequence specific endonucleases. Structural studies of the an 
endonuclease from Escherichia coli (E. coli), EcoRV, revealed an interesting 
conformational change when EcoRV is bound to its target DNA [1]. EcoRV changes 
conformations creating a new binding site for the divalent magnesium ions required for 
cleavage of the target DNA. This conformational change only occurs when EcoRV 
binds to its target-DNA, allowing this enzyme to perform its function with high 
selectivity. This classical example illustrates how natural biological systems have 
evolved to require multiple binding events prior to a recognition event. Inspired by this, 
we propose a binary approach to design selective probes for recognition of detection 
of nucleic acids and proteins.  
The Binary Approach 
This work explores the hypothesis that a binary approach, using two molecules 
that must simultaneously bind a target biopolymer, will improve selectivity over single-
component systems (Figure 1). The general binary scheme requires a target with two 
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ligand-binding sites adjacent to each other (Figure 2). Two analogs of these ligands 
are synthesized, each containing an additional function group. When both ligand 
analogs bind to the target, the additional functional groups are brought in proximity 
creating a recognition event. This event depends on the functional groups used, but 
can be generation of a detectable signal or generation of a new group that can alter 
the activity of the target. In any case, this recognition event only occurs when both 
ligands correctly bind to the target, increasing the selectivity of the recognition event 
since random interactions between the two groups in solution is unlikely to occur. 
Furthermore, it is unlikely that the ligands selected would bind near each other on 
another target. 
It is important to note that all nucleic acids can fulfill the requirement of two 
adjacent ligand-binding sites. Ligands can be designed to bind to the target at a 
specific locus through Watson-Crick base pairing. For proteins, ligands that bind at 
adjacent sites must be available, or efforts must be made to select a new ligand that 
binds near a known ligand. Fortunately, many enzymes naturally facilitate the binding 
of multiple small molecules or macromolecules to perform their function, and thus 
these can be used as ligands to develop a probe following the binary approach. 
Additionally, enzymes are an important drug class and research area. Indeed, up to 
40% of small-molecule drugs target enzymes and an estimated 80% of potential drug 
targets are enzymes [2,3]. Regardless if the target is protein or nucleic acid, the extra 
functional group attached to the ligands can vary greatly in its composition. For 
example, it may consist of an oligonucleotide, reactive small molecule, or a 
4 
fluorescent small molecule. Herein, we explore the binary approach to design probes 
for the selective recognition of nucleic acids and proteins.  
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Figures and tables 
 





Figure 2. Binary approach to design probes for recognition of nucleic acids or 
proteins. 
In a binary approach, two ligands (blue) are created with additional functional groups (half circles). 
Upon binding of both ligand analogs to the target, the additional functional groups are facilitated near 
each other allowing a recognition event to occur. 
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CHAPTER 2: OPERATING COOPERATIVELY (OC) SENSOR FOR 
HIGHLY SELECTIVE RECOGNITION OF NUCLEIC ACIDS† 
Introduction  
The analysis of single nucleotide variation in DNA and RNA is important for 
genotyping of single nucleotide polymorphisms [4,5], somatic mutations [6-8], and 
methylation changes associated with aging and cancer [9-11]. A molecular beacon 
(MB) probe [12] is a hybridization sensor that has been extensively utilized for the 
analysis of single nucleotide variation [13-19]. A traditional MB probe is a stem-loop 
folded DNA oligonucleotide, with fluorophore and quencher dyes conjugated to 
opposite ends (Figure 3A). MB probes have found multiple applications in the analysis 
of biological molecules due to their ability to produce a fluorescent signal 
instantaneously upon hybridization to complementary nucleic acids. MB probes were 
found to be more specific towards single base substitutions than linear probes [20-24]. 
However, in many cases, accurate SNP genotyping still requires elevated temperature 
and/or measuring melting temperature profiles. Moreover, the design of MB probes 
remains challenging due to the problems of stem or loop invasion [16,25,26] and poor 
hybridization with structured sequences [27-31]. Additionally, MB probes are 
expensive commercial products. The use of a limited number of MB probes for the 
                                            
†
 Work in this chapter was previously published: Cornett EM, O'Steen MR, Kolpashchikov DM (2013) 




analysis of numerous target sequences is an attractive perspective. In this approach, 
one, or several, MB probes can be optimized to avoid stem and loop invasion and 
used as universal sensors for any DNA or RNA analytes (so-called universal MB 
probes [32]). This approach may enable multiplex genotyping of millions of SNPs in a 
low budget format. Here we report the design of a sensor that uses a single MB probe 
to detect multiple nucleic acid sequences.  
The sensor has a straightforward design and demonstrates excellent SNP 
selectivity at ambient temperatures. Additionally, this new sensor is suitable for the 
analysis of nucleic acids folded in stable secondary structures, such as bacterial 16S 
rRNA. We have been exploring strategies for indirect binding of an MB probe to 
specific nucleic acids. The first strategy, binary DNA sensors (BDSs), used two DNA 
adaptor strands (m and f in Figure 3B). The f and m strands hybridized to both an MB 
probe and an analyte, forming a DNA four-way junction-like structure (Figure 3B). This 
approach demonstrated unprecedented selectivity at room temperature [32-34]. The 
BDS had a straightforward design and enabled detection of stem-loop folded 
sequences [27,28,34]. The triethylene glycol linkers, situated between the MB-binding 
and analyte binding arms (dashed lines in Figure 3B) were necessary to promote the 
stabilization of the DNA four-way junction conformation that produces high 
fluorescence [32,33]. However, these linkers increased the cost of an adaptor strand 
by a factor of 5. In an effort to avoid the non-nucleotide modification we explored 
alternative approaches, which resulted in the design of a double-crossover (DX) tile 
sensor (Figure 3C) [35,36]. The construct takes advantage of the DX tile, a DNA 
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structure first investigated by Fu and Seeman [37]. The DX tile sensor consisted of an 
MB probe, three unmodified DNA adaptor strands (a, b, and c), and an analyte, which 
together formed a penta-partite complex (Figure 3C). However, the sensor had only 
moderate selectivity towards a single nucleotide substitution due to the required 
formation of at least 26 base pairs between the analyte and the adaptor strands. 
Indeed, long stable hybrids between a probe and a nucleic acid analytes are known to 
reduce probe selectivity [38]. In an effort to design a nucleic acid sensor that is not 
cost-prohibitive, yet still maintains excellent SNP selectivity, we report here a new 
SNP-selective sensor, named ‘operating cooperatively’ or OC sensor (Figure 3D) [39]. 
In this study, we demonstrate the exceptional SNP selectivity of the OC sensor at 
room temperature, determine the limit of detection (LOD), and demonstrate how this 
sensor can be tailored to analyze stem-loop folded DNA and bacterial 16S rRNA.  
Materials and Methods  
Reagents  
All oligonucleotides (sequences listed in Table 1) were custom-made by 
Integrated DNA Technologies, Inc (Coralville, IA). T7 RNA polymerase, PstI, and 
NTPs were purchased from New England Biolabs (Ipswich, MA). Chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO). pEC16SM plasmid was a generous gift 
from Dr. Dedkova (ASU). 
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Fluorescence Assay  
For the fluorescence assays, UMB1 was added to a buffer containing 50 mM 
MgCl2, 50 mM Tris-HCl, pH 7.4, at a final concentration of 50 nM. O and C strands, 
and either matched (rs87T, E.coli f1, rs14G) or mismatched (rs87C, B.sub f1, rs14A) 
strands were added to a final concentration of 200 nM, and 500 nM, respectively. Final 
sample volumes were 120 mL for DNA analytes and 60 mL for bacterial 16S rRNA 
analytes. For assays with DNA analytes, samples were incubated for 15 minutes at 
room temperature (22C). For fluorescence assays with RNA analytes, samples were 
incubated for 5 minutes in 90°C water bath, followed by 15 minute incubation at room 
temperature prior to recording fluorescence spectra. Fluorescence spectra were 
recorded on a Perkin-Elmer (San Jose, CA) LS-55 Luminescence Spectrometer with a 
Hamamatsu xenon lamp (excitation at 485 nm; emission 517 nm). All experiments 
were repeated at least three times, and data is shown as the mean with error bars 
representing one standard deviation from the mean. 
Preparation of Bacterial 16S rRNA Analytes  
Total RNA was isolated from E. coli (ATCC 8739) and B. subtilis (ATCC 9372) 
using Omega Biotek Bacterial RNA isolation kit following the manufacture’s 
recommended protocol. Isolated RNA yield was determined, and the presence of 16S 
rRNA was seen using agarose gel electrophoresis (Figure 5). E. coli 16S rRNA 
transcript was obtained using in vitro transcription with pEC16SM plasmid, which 
contains the 16S rRNA gene from E. coli strain A19. PstI was used to linearize 
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pEC16SM. The in vitro transcription reaction mixture (300 mL) contained linearized 
pEC16SM (1 mg), NTPs (4 mM each), T7 RNA polymerase in NEB RNA pol reaction 
buffer supplemented with MgCl2 (20 mM) and bovine serum albumin (25 mg/mL). The 
reaction was incubated at 37uC for 2 hours. The transcript was collected by ethanol 
precipitation. The concentration of rRNA transcript was determined by comparison of 
gel band intensity with gel purified transcript (Figure 4). 
Results  
 The OC sensor uses two unmodified DNA adaptor strands (O and C), each of 
which binds to a MB probe and a analyte (Figure 3D). The design of the sensor was 
adjusted to room temperature (22°C). For these conditions, strand O had two 5 or 6 
nucleotide MB-binding arms. Thus, the two short binding arms had a very weak 
interaction with MB probe in the absence of analyte, thus ensuring low fluorescent 
background. Strand C had 8 or 9 nucleotide MB binding arms; this length was required 
for the formation of stable DNA four-way junction associates [37]. The analyte binding 
arm of strand C can be adjusted to provide high mismatch selectivity or stabilization of 
the OC complex as demonstrated below. Figure 6A shows a design of the OC sensor 
for the recognition of a human genomic DNA sequence that is known to have a SNP 
(rs876724). This analyte contains a mutation which has been suggested as a useful 
marker for human identification in forensic applications [40]. The sensor fluoresced 
only in the presence of the matched rs87T sequence, but not in the presence of an 
alternative allele (Figure 6B). The limit of detection (LOD) of the sensor was found to 
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be 5.5 nM (Figure 7 blue line), which is somewhat above the detection limit of a typical 
MB probe [12-16,32]. Importantly, the presence of high excess (500 nM) of a single-
based substituted analyte did not jeopardize the assay: the cognate analyte was 
detected with the LOD of 12 nM (Figure 7 red line). Importantly, the LOD is well below 
the concentration achievable by PCR (~100 nM). In order to demonstrate general 
applicability of the approach, an OC sensor was designed to recognize an alternative 
human SNP (rs1490413 Figure 8). Again, the sensor demonstrated excellent SNP 
discrimination at room temperature. The design of the new sensor was 
straightforward: (i) the sensor utilized the same MB probe; (ii) only the analyte binding 
arms of the sensor were changed to complement to the new target. 
Natural single stranded nucleic acids are often folded in stable secondary 
structures. Stable structures prevent hybridization probes, including the MB probe, 
from interacting with such analytes [27-30,41]. A common approach to overcome this 
difficulty is to target only unstructured fragments of natural RNAs. This limits the 
choice of hybridization probes and often prevents analysis of SNPs located in stem 
regions of such analytes. Here we demonstrate that the OC sensor is capable of 
analyzing folded nucleic acids. As a model, a fragment of E. coli 16S rRNA (E. coli f-1 
in Figure 9A) was used as a specific analyte and a corresponding fragment of B. 
subtilis 16S rRNA (B. sub f-1 in Figure 9A) was used as a non-specific analyte. These 
analytes were DNA olignonucleotide mimics of the actual RNA sequence. Analysis of 
16S rRNA is important for classification of bacteria species and for molecular 
diagnostics of infectious diseases [42-45]. On the other hand, 16S rRNAs, as well as 
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their DNA amplicons, can fail to hybridize to oligonucleotide probes [46,47]. In this 
study, we have randomly selected a fragment of E. coli 16S rRNA folded in a typical 
stemloop structure with a bulge in the middle of the stem (Figure 9A). The predicted 
melting temperature of this stem was 84.5°C according to IDT Oligo Analyzer software 
(experimental conditions set at 50 mM MgCl2, 50 mM monocharged ion). 
The OC sensor for selective recognition of the stem-loop folded E. coli f-1 took 
advantage of a C2 strand equipped with a long analyte binding arm, containing 30 
nucleotides (Figure 9B). The long arm allows the C2 strand to tightly hybridize to an 
extended portion of the analyte and unwind its secondary structure. However, the long 
arm may also allow a stable complex to form between C2 and B.sub f-1 analyte. Thus, 
the O2 strand is designed to contain an analyte binding arm of only 12 nucleotides 
and will hybridize tightly only to the fully complementary E.coli f1. Indeed, high 
fluorescence was registered only in the presence of a fully matched strand, but not in 
the presence of a mismatched B.sub f-1 (Figure 9C).  
In order to test the OC sensor against actual bacterial 16S rRNA samples, we 
used in vitro transcription to obtain E. coli 16S rRNA. The OC sensor was able to 
recognize and give high fluorescent signal in the presence of the 16S rRNA transcript 
(Figure 10A). However, an additional annealing step was required, likely due to a very 
stable structure of the long 16S rRNA compared to our mimic analytes. Additionally, 
the OC sensor was applied to the identification of 16S rRNA collected from bacteria 
samples. The total RNA from E. coli and B. subtilis was obtained and the OC sensor 
correctly identified the E. coli 16S rRNA. The OC sensor produced a high fluorescence 
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signal in the presence of E. coli RNA, but gave a low signal in the presence of B. 
subtilis RNA or no analyte (Fig. 6B). Thus, the OC sensor is suitable for sequence 
selective recognition of conformational constrained natural RNAs. 
Discussion 
MB probes have become an important tool of molecular diagnostics, especially 
in real-time PCR (rtPCR) format [13,15]. However, the application of MB probes in 
practice suffers from a number of problems including stem invasion and inability to 
analyze folded RNA and DNA. Moreover, despite improved selectivity towards 
mismatched analytes, MB probes still require monitoring of melting profiles for 
accurate SNP genotyping [13-15]. Multicomponent sensors that use indirect binding of 
an MB probe to a target DNA or RNA analyte offer a solution for these pitfalls. In this 
approach, a limited number of optimized MB probes can provide a toolbox for the 
analysis of millions of human and bacterial SNPs with no need to design a pair of 
unique MB probes for each new SNP of interest. 
Previously, our lab introduced two different designs for MB probe-based 
multicomponent sensors, each with its respective disadvantages[33,35]. The OC 
sensor reported here demonstrated marked improvement over the previous designs: it 
is less expensive than binary DNA sensor and more selective towards SNPs than a 
DX-tile sensor. Additionally, the OC sensor is suitable for the analysis of secondary 
structure folded DNA and RNA. Herein, the utility of the OC sensor was demonstrated 
by adapting an OC sensor for detection of bacterial 16S rRNA. Therefore, the 
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approach described in this study has potential to become useful for instantaneous 
detection of nucleic acids in homogeneous solutions. OC sensors used in this study 
were designed to operate at room temperature to avoid any required temperature 
control for the hybridization reaction between probes and analyte. However, the 
design could likely be adjusted to function at elevated temperatures (50–60°C) for 
applications such as quantitative real time PCR. 
The OC sensor produces fluorescent signal instantaneously upon hybridization 
to a specific nucleic analyte. The MB probe binds to the analyte indirectly, e.g. through 
two unmodified DNA oligonucleotide adaptor strands. This gives an opportunity to 
optimize a single MB probe for the analysis of multiple DNA or RNA sequences. The 
approach provides a versatile tool for nucleic acid analysis at ambient temperature 
that is SNP specific and capable of analyzing stem-loop folded nucleic acids. Thus the 
OC sensor represents a promising tool for SNP analysis in homogeneous solution, 
which might be used for detection and genotyping of bacteria or human SNPs.  
16 
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Figure 3. Molecular beacon-based sensors for nucleic acid detection. 
A) Conventional MB probe [12].  
B) MB-based binary DNA sensor (BDS) [33]. Dashed lines indicate triethylene glycol linkers.  
C) DX-tile based sensor [35].  




Table 1. Sequences of oligonucleotides used in the OC sensor study. 
Name  Sequence  Purification  


























O1 5'-TATTGTTATACTTCAGTGGCGATC  SD 
C1 5'-AATATACTATGTTAACG  SD 





O3 5'-TATTGTAAGAACCCACATGCGATC  SD 




Figure 4. E. coli 16S rRNA in vitro transcript concentration was determined 
using agarose gel electrophoresis. 
In vitro E. coli 16S rRNA transcript concentration determination by 1% agarose gel electrophoresis with 
GELRED staining. Transcript was gel purified and concentration determined using a 
spectrophotometer. Several concentrations of known gel purified transcript (lanes 1–4), as well as 1 µL 
from two dilutions of unknown concentration used in the fluorescent assays. The 1/8 dilution sample 
was determined to be equal in intensity to 166 ng band. This was used to determine the concentration 








Figure 6. OC sensor selectively recognizes rs876724 SNP T allele. 
A) Sensor in complex with rs87T analyte and UMB1 probe. The sensor was designed to recognize the 
thymidine containing allele, while discriminating against the alternative cytosine containing allele. 
MB-binding arms are shown in cyan.  
B) Fluorescent response of OC sensor specific to rs87T allele sequence in the absence or presence of 
specific or non-specific analytes. 







Figure 7. OC sensor limit of detection (LOD). 
O1, C1, and UMB1 probe were used to analyze low concentrations of the matched analyte (rs87T). The 
limit of detection (LOD) was calculated as the analyte concentration that triggered a fluorescent signal 
equal to the average fluorescence of the background from three independent measurements plus three 
standard deviations of the average back- ground fluorescence. Data shown were plotted as the mean 
with error bars representing one standard deviation from the mean from three independent trials. LOD 
was determined in the absence (blue line) or in the presence (red line) of 500 nM of mismatched 
analyte (rs87C). The green dashed lines represent the respective thresholds and the black dashed lines 




Figure 8. Design and validation of an OC sensor to selectively recognize 
rs1490413 SNP. 
A) Signal-to-noise ratios for OC sensor designed to detect human genomic SNP rs1490413 allele G.  





Figure 9. Design and validation of an OC sensor for recognition of secondary 
structure-forming fragment of E.coli 16S rRNA. 
A) Sequences and the predicted secondary structure of stem-loop folded fragments of 16S rRNA. The 
nucleotide variations in E. coli and B. subtilis 16S rRNA are shown in magenta. 
B) OC sensor in complex with fully matched E.coli f-1 sequence. MB binding arms of strands O2 and 
C2 are shown in cyan.  
C) Signal-to-noise ratio of fluorescent response of OC sensor in the presence of absence of E.coli or 
B. subtilis 16S rRNA mimics. The assay was conducted in 50 mM Tris HCl, pH 7.4, 50 mM MgCl2 at 
room temperature (22°C). The data represents the signal-to-noise ratios of three independent 
experiments with error bars indicating one standard deviation from the mean.  
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Figure 10. An OC sensor selectively recognizes bacterial 16S rRNA. 
A) Fluorescent response of OC sensor in the present of various concentrations of E. coli 16S rRNA 
generated by in vitro transcription in vitro transcript. Graph depicts the mean fluorescence of three 
independent experiments. Error bars represent the standard deviation. 







CHAPTER 3: MOLECULAR LOGIC GATES FOR DNA ANALYSIS: 
DETECTION OF RIFAMPIN RESISTANCE IN M. TUBERCULOSIS 
DNA‡ 
Introduction  
Molecular logic gates made of DNA have attracted significant attention because 
of their biocompatibility, simple design, and ability to analyze and control biological 
systems [48-54] To fuel further development of the field, applications of DNA-based 
gates to solve significant biological problems are required. Recently, our lab 
characterized a set of DNA logic gates (YES, NOT, AND, and OR) and demonstrated 
their connectivity by designing ANDNOT and XOR operations [53,54]. The gates used 
hybridization of DNA strands with a molecular beacon (MB) probe to produce a 
fluorescent output. Herein, DNA logic gates are applied to solve an important 
biomedical task: analysis of multiple DNA sequences containing a complex set of 
mutations. 
Mycobacterium tuberculosis (Mtb) infects approximately 2 billion people all over 
the world and is responsible for about 2 million deaths each year [55]. Approximately 
10% of all patients are infected by strains of Mtb that are drug-resistant; these strains 
are primarily resistant to antibiotics rifampin (Rif) and isoniazid [55]. Currently, there is 
                                            
‡ Work in this chapter was previously published: Cornett EM, Campbell EA, Gulenay G, et al. (2012) 
Molecular logic gates for DNA analysis: detection of rifampin resistance in M. tuberculosis DNA. Angew 
Chem Int Ed Engl 51:9075–9077.  
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an urgent need for cost-effective diagnostic methods that can detect Mtb in clinical 
samples and differentiate between drug-susceptible and drug resistant Mtb strains 
[56-60]. Several assays exist to detect mutations responsible for antibiotic resistance 
[56,58-62]. One of the most advanced commercial assays, Cepheid’s Expert MTB/RIF 
[63-66], takes advantage of real-time PCR (rtPCR) and MB probes [13,67]. MB 
probes, first introduced by Tyagi and Kramer [12], are stem–loop-folded 
oligonucleotides with fluorophore and quencher dyes attached at opposite ends 
(Figure 11). Hybridization of an MB probe to a complementary DNA or RNA switches 
the probe to an elongated form, thus separating the fluorophore from the quencher. 
The resultant fluorescence increase can be quantitatively measured, which is the 
basis for the widespread application of MB probes in real-time detection of nucleic 
acids. In the Expert MTB/RIF assay, five MB probes were designed to span the highly 
variable 81-nt core of the bacterial amplicon where approximately 96% of all Rif-
resistant mutations are located (Figure 11A). The probes were complementary to the 
drug-susceptible wild-type (WT) sequence [68]. A signal from all five MB probes 
indicated the presence of the WT (no mutation in the core region). Absence of a signal 
from all five probes indicated that a sample was Mtb negative. Failure of at least one 
MB probe to produce a signal indicated the presence of a Rif-resistant Mtb (Figure 1A, 
right). Formal logic suggests that the Expert MTB/RIF process is redundant: it uses 
five outputs to answer “yes” or “no” to the two following questions: 1) Is there Mtb DNA 
present in a sample? 2) Does the Mtb DNA contain a mutation that confers rifampin 
resistance? Additionally, five expensive, hard-to-optimize MB probes along with a five 
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channel fluorescent reader are needed for the assay. Formally, the task can be 
executed by using only two outputs. Herein we propose to use a DNA-based YES 
logic gate to answer the first question and an OR logic gate to answer the second 
question. Each gate uses a separate fluorescent output, thus the detection process 
requires only two MB probes. 
Materials and Methods  
Materials  
All of the oligonucleotides were custom-made by Integrated DNA Technologies, 
Inc (Coralville, IA). Standard reagents for buffers were purchases from Fisher 
Scientific. DNA grade water was used for preparation of al samples and buffers. The 
sequences of all strands of the proposed oligonucleotide sensor as well as analytes 
are given in Table 2. 
Fluorescence Assay 
For the fluorescence assay with both YES and OR logic functions combined, all 
five M strands (50 nM), three F strands (200 nM), strands C, D (200  nM each), and E 
(100 nM), UMB1 (25 nM), and UMB2 (25 nM) were mixed in a buffer containing 50 
mM MgCl2, 50 mM Tris-HCl, pH 7.4, in the presence or absence of 250 nM wild-type 
(WT) or mutant analyte (M1–M5). Final sample volumes were 120 mL. Fluorescence 
spectra were recorded on a PerkinElmer (San Jose, CA) LS-55 luminescence 
spectrometer with a Hamamatsu xenon lamp (excitation at 550 nm; emission at 580 
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for UMB1 and excitation at 485 nm; emission 517 nm for UMB2) after 15 min 
incubation at room temperature (22C). The data was analyzed using Microsoft Excel. 
The means of three independent experiments were calculated and converted to 
signal-to-background Figure 2. The background was considered the sample with all 
oligonucleotides except analyte. All signals above a threshold set at S/B=1.5 were 
considered true outputs for either the YES or the OR logic gates.  
Results 
Analyte WT represents wild-type Mtb sequence with no resistance-causing 
mutations. All five mutant sequences (named here M1–M5; see Table 2) were from 
the highly variable 81-nt core, each with a separate known mutation that confers Rif 
resistance. They were previously used for characterization of Rif resistant Mtb strains 
by conventional methods [61,62,68-71]. The YES logic gate consisted of the three 
DNA stands (a, b, and c in Figure 11B) and a universal MB probe (UMB1). In the 
presence of any Mtb DNA, either WT or Rif-resistant M1–M5, the three strands formed 
a complex with the target DNA and UMB1. The fluorescent complex that contained 
UMB1 had an arrangement of DNA strands similar to a DX tile,[7] which our lab 
recently studied [35]. Importantly, the DX complex was tolerant to mutations since it 
formed a long 36 base pair hybrid with the analyte (Figure 14). The OR gate was 
designed to report the presence of any of the five different drug resistance-conferring 
mutations across all three separate regions within the hypervariable 81-nt region of 
the Mtb genome. The OR gate consisted of O and C strands. Each C strand was 
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designed to recognize a specific mutant strain of Mtb that is known to cause Rif 
resistance. Together, the five C and the three O strands formed five fluorescent 
complexes with UMB2 and the five Mtb mutants, M1, M2, M3, M4, and M5 (Figures 12 
and 13). Each fluorescent complex was formed only in the presence of the cognate 
mutant analyte, but not WT. Therefore, overall performance of the complete set of all 
O and C strands corresponded to OR logic, which produced a high fluorescent output 
in the presence of any Mtb DNA containing one of the 5 selected SNP that confer Rif-
resistance, but low in the presence of WT. Pairs of O and C strands were optimized to 
produce high signals only in the presence of cognate mutant sequence (Figures 12 
and 13). Two different O strands, M1_M4-O and M2_M3-O were utilized as uniform 
components for recognition of M1, M4 or M2, M3, respectively. Importantly, no signal 
above the background was produced by the WT Rif-susceptible sequence (Figures 12 
and 13). This was achieved by designing relatively short analyte-binding arms of all M 
strands (7 nucleotides), which increased sensitivity for a mutation (Figure 12).  
To create a functional assay, all DNA strands of both the YES and OR gates 
were combined with UMB1 and UMB2 in one reaction mixture and the outputs of the 
UMBs were measured at two different wavelengths (517 nm and 580 nm). Both the 
OR and YES gates functioned according to the design: the YES gate produced high 
output at 580 nm in the presence of both WT and the mutant sequences (Figure 15, 
gray bars); the OR gate generated high signal at 517 nm in the presence of any of the 
mutants but a low signal for the WT analyte (Figure 15, black bars). Therefore, the 
combination of the YES and OR gates produced a high signal at 580 nm if any Mtb 
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sequence is present, whereas a signal at 517 nm was observed only if a Rif resistant 
mutant sequence was present. This signal pattern can be unambiguously used for 
diagnostic purposes to answer the questions of the presence of an Mtb sequence and 
its Rif susceptibility. 
Discussion 
PCR-based Mtb analysis is considered to be a new method to replace time 
consuming culturing or error-prone sputum smear microscopy techniques [57,69]. The 
Expert MTB/RIF assay can detect Mtb resistance in 2 hours with high selectivity [63-
65,72-74]. However, the approach is limited to interrogation of the 81- nt hypervariable 
fragment of the Mtb genome. Detection of other mutations (for example, mutations 
responsible for isoniazid resistance) would require introduction of additional MB 
probes, while current rtPCR instruments register fluorescence from only a few (5 or 6) 
channels. Importantly, if a sample is contaminated with the WT sequence, the assay 
would produce a false negative for antibiotic resistance, as all five MB probes would 
preferably bind the WT analyte, producing high fluorescent signal. Herein we propose 
the combination of YES and OR DNA logic gates to achieve accurate detection of both 
WT and Rif-resistant  Mtb DNA sequences (Figure 16). The approach minimizes the 
number of MB probes required for both the detection of Mtb and Rif resistance. 
Therefore, a qPCR instrument with five detection channels can be replaced with a 
more affordable two-channel thermal cycler. Alternatively, additional OR gates can be 
designed to recognize other antibiotic-resistant Mtb strains if a multichannel qPCR 
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instrument is available. Thus, the study presented herein can serve as the framework 
for the development of a multiplex assay to determine Mtb presence as well as drug 
resistance for all major first-line antibiotics. A multiplex assay of this nature would be a 
valuable tool for health care providers. In either case, the presented approach is cost-
efficient as the logic gates use unmodified DNA as adaptor strands, which are 
inexpensive synthetic oligonucleotides. Earlier, our lab reported the design of DNA 
logic gates that take advantage of MB probes as fluorescent reporters [27,28,32,33]. 
However, the constructs used expensive non-nucleotide modifications, which added to 
the cost of custom-made oligonucleotides. The combination of adaptor strands O and 
C reported herein is a new cost-efficient OR gate that demonstrates robust 
performance. Impressively, the 13 oligonucleotides working together in solution clearly 
demonstrated predictable digital response with no detectable crosstalk. 
We anticipate that the use of additional strands for detection of other mutations, 
including those responsible for resistance to isoniazid and other antibiotics, will not 
compromise the performance of the assay. Indeed, the complex predesigned DNA 
associates of hundreds of self-assembling DNA strands can be produced at a yield of 
more than 90% [75,76]. Among numerous DNA logic gates reported to date, there are 
few applications to solve challenging practical problems. We have demonstrated that 
the combination of DNA logic gates can be used to perform a complex diagnostic task 
efficiently, affordably, and reliably. This work is a step towards employing logic gates 
as versatile tools for diagnosis of tuberculosis and other infectious diseases, which 
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Figures and tables 
 
Figure 11. Molecular Beacon (MB) probe-based strategies for analysis of Rif-
resistant Mtb.  
A) Expert MTB/RIF five MB probe approach [63-65,74]. Absence of a signal from at least one MB 
probe (for example, MB5) indicates the presence of Rif-resistant Mtb DNA.  
B) Combination of YES and OR logic gates for the detection of Mtb and its resistance to Rif. The three 
DNA strands (a, b, and c) form a complex with UMB1 and the analyte to report the presence of Mtb 
DNA. A pair of O and C strands of the OR gate forms fluorescent complex with UMB2 and the 
analyte only if a mutation responsible for Rif-resistance is present in the sequence. SNP = single 





Table 2. Sequences of oligonucleotides used in the DNA logic gate for Mtb DNA 
analysis study. 
Name Sequence Purification 




UMB 2  5’-/FAM/GCGTTAACATACAATAGATCGC/BHQ1/  HPLC  
UMB 2’  5’-/FAM/GCGTTAACATACAATAGATCGC  SD  
a  5’-TGGCTGTGCTCAGCTGGCTG G  SD  
b  5’ TTCGACATGAATTGGCTTTG  SD  
c  5’- GTTGTTCTGGTCTGATTCCA  SD  
M1_M4-O  5‘-TATTGTGTCGGCGCTTGTGCGATC  SD  
M2_M3-O  5’-TATTGTGCGGGTTGTTCTGCGATC  SD  
M5-O  5‘-TATTGTGAATTGGCTCAGGCGATC  SD  
M1-C  5’-GCCCACAATGTTAACG  SD  
M2-C  5’-CCCAACAATGTTAACG  SD  
M3-C  5‘-CCCTGCAATGTTAACG  SD  
M4-C  5‘-GCCAACAATGTTAACG  SD  



































Figure 12. Design and performance of OR gate component for recognition of M1 
analyte. 
A) Fluorescent output and the complex formed by the OR gate component with M1 analyte. Strands 
M1_M4-O and M1-C (200 nM) and UMB2 (25 nM) were incubated in the absence (red) or presence 
of 500 nM WT (pink) or mutant M1 (green). Control sample (blue) contained only UMB2 (25 nM). 
Spectrum of fluorescent output between 500 and 550nm with 485nm excitation was recorded after 
15 minute incubation.  
B) Graph depicts the mean of three independent measurements with one standard deviation for 
fluorescent output at 517nm.  
C) Native polyacrylamide gel electrophoresis (nPAGE) analysis of OR gate performance. Samples 
were mixed as described in the Materials and Methods with UMB2 replaced by UMB2’ (no 
quencher, see table 2 for the sequence). Samples contained the following oligonucleotides: Lane 1: 
UMB2’; Lane 2: UMB2’, M1_M2-O and M1-C; Lane 3: UMB2’, M1_M4-O, M1-C and M1; Lane 4: 
UMB2’, M1_M4-O, M1-C and WT; Lane 5: M1_M2-O; Lane 6: M1-C; Lane 7: M1. After 15 minute 
incubation at room temperature, 20μL of nPAGE-loading buffer (50% glycerol, 50mM Tris-HCl pH 
7.4, 50mM) was added to each sample. A total of 120μL of each sample was loaded into an    
nPAGE (1.5 mm thick) and run for 30 min at 100   with 4  C water circulating through a Thermo-Owl 
PD9S gel electrophoresis apparatus. The gel picture was taken without staining using a U:Genius 
gel documentation instrument. The fluorescent complex corresponding to the tetrapartite associate 
is indicated by the arrow.  




Figure 13 Fluorescent output of OR gate components for M2-M5. 
Corresponding strands O (200 nM), C (100 nM) and UMB2 (25 nM) were incubated in the absence 
(red) or presence of WT (pink) or a mutant (green) (500 nM). Control sample (blue) contained only 
UMB2 (25 nM). Fluorescent output at 517 nm with 485 nm excitation was recorded after 15 min 





Figure 14. Design and performance of YES logic gate for recognition of Mtb  WT 
DNA sequences. 
A) Fluorescent output from YES gate in the presence or absence of the DNA analytes. Strands a, b 
(200 nM), c (100 nM) and UMB1 (25 nM) were incubated in the absence (red) or presence of 
mutants M1-M5 or WT analytes (500 nM). Control sample (blue) contained only UMB1 (25 nM). 
Fluorescent output at 580 nm with 550 nm excitation was recorded after a 15 minute incubation at 
room temperature. Graph depicts the mean of three independent measurements with one standard 
deviation.  





Figure 15. Combination of YES and OR gates for detection and mutation 
analysis of Mtb DNA. 
All OR gate, YES gate, UMB1, and UMB2 oligonucleotides were mixed together in the absence or 
presence of each separate mutant or wild-type analytes. Fluorescence at 580nm for UMB1 (gray) or 
517nm for UMB2 (black) was recorded after a 15 min incubation at room temperature. The graph 
depicts the mean signal-to-background ratio (S/B) of three independent measurements. Error bars 
represent the standard deviation. S/B was calculated as a ratio of fluorescence in the presence of 




Figure 16. Graphical representation of logic gate scheme for detection and 
mutation analysis of Mtb DNA. 
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CHAPTER 4: BINARY REAGENTS FOR INACTIVATION OF HIV-1 
REVERSE TRANSCRIPTASE  
Introduction  
 Design and development of probes that selectively recognize and subsequently 
block a protein’s function are important for research and drug discovery. Classical 
approaches have focused on optimization of inert small molecules that form non-
covalent interactions with their target leading to only moderate affinity and reversible 
inhibition of the target’s biological function. Interestingly, some of the most successful 
commercial drugs interact with their targets through covalent interactions, so-called 
“covalent inhibitors” [77-79]. Most of the covalent inhibitors currently approved for use 
as drugs were discovered serendipitously. Recently, concerted efforts by academia 
and industry have been made to rationally design and develop new covalent inhibitors 
[77,78]. The main impetus behind the newly minted interest in covalent inhibitors is 
due to the advantages they offer. These include lower dosing, uncoupling of 
pharmacokinetics (PK) and pharmacodynamics (PD), and decreased likelihood of 
resistance being formed against the inhibitor [77,80]. The limiting factor in wide-scale 
development of covalent inhibitors is selectively controlling the formation of the 
covalent bond with only a specific target. The predominant mechanism of action for 
covalent inhibitors is inclusion of an electrophilic moiety capable of reacting with 
nucleophilic amino acids on target proteins. Thus, the wide distribution of such amino 
acids throughout the proteome causes difficulties achieved the necessary selectivity 
for use as drug leads or chemical probes. Others have addressed this issue by using 
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bioinformatics to select targets that contain a requisite nucleophilic amino acid that is 
not present in similar proteins [77,81]. This ‘targeted covalent inhibitor” (TCI) approach 
has found success in developing covalent inhibitors for kinases. The range of proteins 
that can be targeted with the TCI approach is limited by the requisite of a unique 
nucleophilic amino acid side chain. We hypothesize that a binary approach to 
developing covalent inhibitors will allow a greater flexibility in designing probes to 
selectively recognize and inhibiting a specific target.  
Design of covalent inhibitors using the binary approach. 
In this application of the binary approach, two analogs of ligands (Figure 2) that 
bind adjacent sites of the target are conjugated to pre-reactive groups. These pre-
reactive groups (Figure 2 half circles) are small molecules that fulfill three criteria. 
First, it is necessary that pre-reactive groups be inert toward water and biological other 
molecules. Second, pre-reactive groups should react with each other when in 
proximity and proper orientation. Finally, the reaction between pre-reactive groups 
should produce a new chemical group that is capable of reacting with, or modifying, 
amino acid side changes, protein backbone, or nucleic acid backbone (recognition 
event). Thus, upon binding of both ligands to the target, the pre-reactive groups will be 
in proximity to react and form a reactive intermediate that subsequently reacts with 
amino acids on the target, inhibiting its function. We recently reported a light-activated 
two-component covalent inhibitor designed following the binary approach that inhibits 
of T4 DNA polymerase. Importantly, we were able to directly compare a classical 
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single covalent inhibitor approach to the binary approach and found significant 
improvement in the selectivity of the binary inhibitor. The light-activated compounds 
are useful for some research applications, however, it is our goal to develop a similar 
inhibitor utilizing chemistry that does not require light. Such, light-free binary covalent 
inhibitors would be useful as chemical probes for research and potentially as drug 
leads. Herein, the binary approach is applied to the design of covalent inhibitors for 
HIV-1 reverse transcriptase (RT), an important drug target and excellent model for 
designing covalent inhibitors using the binary approach. 
HIV-1 Reverse Transcriptase: a model target for the binary approach. 
We chose HIV-1 reverse transcriptase (RT) as a model target because it is 
especially amenable to targeting using a binary approach, is an important drug target, 
and its activity is easily assayed in a variety of formats. RT is the enzyme responsible 
for retrotranscription of the single stranded RNA genome of HIV. To accomplish this 
critical task in the HIV life cycle, RT coordinates three separate enzymatic activities: 
RNA-dependent DNA polymerase activity, ribonuclease H acitivty, and DNA-
dependent DNA polymerase activity [82,83]. RT is an asymmetric heterodimer with 
66kDa and 51kDa subunits; the latter is a cleavage product of the former. RT has the 
characteristic DNA polymerase structure, resembling a right hand with finger, palm, 
and thumb substructures (Figure 17). The mechanism of RT polymerization is similar 
to the mechanism described for other DNA polymerase. The polymerase active site is 
located in the palm domain, and contains a triad of aspartic acid residues with 
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coordinate magnesium ions required for synthesis. A primer and template DNA or 
RNA bind to the finger domain, positioning the 3’-hydroxyl (3’OH) of the priming strand 
at the active site. Near the active site and the critical aspartate residues lies the 
nucleotide-binding site, where deoxynucleotide triphosphates (dNTPs) bind. Upon 
binding of a dNTP that forms the correct Watson-Crick base pairing with the first free 
base in the template strand, the confirmation of RT changes. The confirmation change 
positions the 3’OH of the primer in the proper position to attack the alpha phosphate of 
the incoming dNTP, forming a phosphodiester bond [82]. The structure and function of 
RT make it an excellent target for applying the binary approach. Moreover, RT is an 
excellent model to test new pre-reactive group chemistries.  
The design of a covalent inhibitor for RT following the binary approach takes 
advantage of the two natural ligand binding sites located near each other: the 3’ end of 
the primer and the nucleotide binding site (Figure 17C yellow and green). Thus, the 
two components of the inhibitor are analogs of the natural RT substrate: nucleotide 
triphosphates. We chose dTTP since previous studies have shown that modification of 
dTTP can be routinely accomplished and modified dTTP is still a suitable substrate for 
many DNA polymerases, including RT. The RT will incorporate one of the dTTP 
analogs and translocate down the template strand, moving the first component into the 
first binding site, the 3’ end of the primer. Upon binding of the second component to 
the nucleotide binding site, the two pre-reactive groups attached to the dTTP analogs 
will be positioned close to each other, allowing them to react. This reaction should 
generate a reactive chemical that subsequently reacts with available amino acid side 
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chains on RT. Analysis of reported structures of RT show that two lysine residues 
(Lys66 and Lys65) are nearby these binding sites and may be able to react under 
proper conditions (Figure 17C Lys66 and Lys65).  
HIV-1 RT Inhibitors 
Current RT inhibitors are delineated into two classes: nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) [84,85]. NRTIs are delivered as nucleosides and phosphorylated to 
respective nucleotide triphosphates by cellular kinases. NRTIs are known as “chain 
terminators” due to their mechanism of action. NRTIs are competitive inhibitors that 
once phosphorylated, compete with natural dNTPs for binding to the nucleotide-
binding site on RT (Figure17C yellow). However, NRTIs lack a 3’OH, preventing any 
further elongation, thus inhibiting its polymerase activity. NNRTIs are noncompetitive 
inhibitors that bind at an allosteric site nearby the polymerase active site and are 
thought to promote a conformational shift that decreases the polymerase activities of 
RT. NNRTIs are highly prone to the development of resistance, but are still useful for 
use in patients that are treatment naïve [86]. NRTIs are also prone to the the 
development of resistance, but less so than NNRTIs. A major downside to NRTIs is 
side effects associated with NRTI inhibition of the mitochondrial DNA polymerase 
gamma [87,88]. However, NRTIs, the first RT inhibitors discovered, remain a critical 
tool in treating HIV. Thus, despite the success of current HIV treatment regimens and 
RT inhibitors, RT remains an important drug target that warrants further efforts to 
develop new inhibitors. Particularly, RT is an excellent candidate to pursue 
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development of covalent inhibitors, as this could directly address many of the current 
limitations inhibitors. Thus, we chose RT as a model target to develop binary covalent 
inhibitors. 
Materials and Methods 
Materials 
All chemical were purchases from Sigma Aldrich or Fisher Scientific. The CA, 
SB, and TF dTTP analogs were custom synthesized in the Kolpashchikov Lab by 
Carlos Ledezma. All other dNTPs were from Promega or New England Biolabs. The 
AZT triphosphate was purchased from ChemCyte.  
Gel Analysis of HIV-1 RT Elongation Products 
Samples (typically 15 μL) contained 50nM of HIV-1 RT (Worthington 
Biochemical Corporation), 1 μM of FAM-primer(FAM-Primer: 5’/FAM/ GTC CCT GTT 
CGG GCG CCA) and template (5’-C TGT GTG GTC GTT CTC TTG CTA TGG GCG 
CCG AAC AGG GAC) in HIV RT RXN buffer (50 mM Tris pH8.3, 8 mM MgCl2, 40 mM 
KCl). FAM-primer was purified by HPLC. For CA-TF experiments, 5μM of each CA, 
TF, or dTTP analog was added, as indicated, followed by incubation at 37 °C. Aliquots 
of each sample were removed at indicated time points (5, 10, 20 and 30 minutes) and 
500μM of natural dNTPs were added. After incubation at 37 °C for an additional hour, 
samples were quenched by addition of an equal volume of 2X dPAGE Loading Buffer 
(LB) (95% Formamide, 20 mM EDTA (pH 8.0), 0.05% bromophenol blue). For SB-TF 
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experiments the first analog was added to a final concentration of 10 μM followed by 
30 minute incubation at 37 °C. The second analog was added to a final concentration 
of 100 μM followed by 60 minute incubation at 37 °C. Next, 500 μM of all four natural 
dNTPs (dATP, dCTP, dGTP, dTTP) were added to each sample, as indicated, and 
incubated for 60 minutes at 37 °C. To stop the polymerase reaction, an equal volume 
of 2X dPAGE LB was added to each sample. Control samples to evaluate elongation 
by one base were quenched with dPAGE LB after the initial incubation period. For 
both CA and SB experiments, all samples were heated for 5 minutes prior to loading 
15 μL onto a 15  7 M urea denaturing PAGE gel that was typically run for 45 minutes 
(or until sufficient separation as indicated by migration of bromophenol blue) at 400 V 
with 55 °C water running through a Thermo Owl Electrophoresis apparatus. Gels were 
rinsed in deionized water and visualized using a Syngene U:Genius Gel 
documentation instrument which allowed detection of the fluorescently labeled FAM-
primer with no additional staining. 
Molecular Beacon Assay for HIV-1 RT Activity 
Samples (typically 50 μL) contained 50 nM of HIV-1 RT (Worthington 
Biochemical Corporation), 100 nM of MB probe, and 110 nM of 12-nt Primer 
(sequences found in Figure18A) in HIV RT RXN buffer (50 mM Tris pH8.3, 8 mM 
MgCl2, 40 mM KCl). CA, TF, dTTP, or AZT was added as indicated and samples were 
transferred into wells of a ThermoNunc 96 well flat black polystyrene micro plate. After 
a 5 minute incubation at 37 °C, 100 μM of dNTPs were added to each sample and 
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fluorescent intensity was recorded at 517 nm (485 nm excitation) using an Infinite 200 
Pro plate reader. After 30 minutes, an additional aliquot of MB and 12nt 
primer/template mix were added to each sample and fluorescent intensity was 
recorded for an additional 30 minutes. Validation of the assay is shown in Figure 18B.      
Molecular Dynamics Simulation 
Molecular Dynamics simulations were conducted using the Protein Databank 
(PDB) structure 1RTD. 1RTD is a solved crystal structure of a ternary HIV-1 RT 
structure containing RT, primer-template, and dTTP bound to the nucleotide-binding 
site. Figure 19 shows the MD workflow used in this study. Each step is explained in 
detail below. First, the dTTP ligand analogs were drawn in Chemaxon MarvinSketch, 
cleaned in 3d, and exported to the PDB file format. Visual Molecular Dynamics (VMD) 
(http://www.ks.uiuc.edu/Research/vmd/) [89] was used to align the thymidine base of 
the ligand analogs with the base of the dTTP from the 1RTD structure. The newly 
aligned dTTP analogs were saved, and the atom information (coordinates) of the base 
and pre-reactive group was copied into the 1RTD PDB file followed by deletion of the 
original dTTP base atoms and coordinates. The original ribose and triphosphate of the 
dTTP in the 1RTD structure was kept in place as the best approximation of the 
orientation that the triphosphate group of the dTTP analogs would assume. This 
procedure was repeated for building structures that contained analogs translocated 
one position into the primer as well as in the active site. Four total structures were built 
(dTTP, SBdTTP, TFdTMP-SBdTTP, and SBdTMP-TFdTTP). After building the 
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structures, they were placed in a water box using VMD. The CHARMM force field 
[90,91] was used and ParamChem’s CGenFF program (cgenff.paramchem.org; 
interface version 0.9.7.1 with force field 2b8) [90,92-94] generated the topology and 
parameter files for the new pre-reactive groups. As with the structure, these parameter 
and topology files were joined with the base and ribose from the general force field. 
The VMD psfgen plugin was used to generate a PSF file for each system. NAMD 
Molecular Dynamics Software (http://www.ks.uiuc.edu/Research/namd/) [95] was used 
to perform MD simulations on the Stokes HPC at the University of Central Florida 
Advanced Research Computing Center (UCF ARCC).  NAMD of each strcutre was run 
to minimize, equilibrate water, release constraints, fully equilibrate, and finally obtain 
production MD data (Figure 19).  
Results 
Clavulanic acid (CA) and 2,3,5,6-Tetrafluoro-4-hydroxy-benzoic acid (TF) 
pre-reactive group pair 
Initially, the natural product clavulanic acid was selected as an ideal candidate 
for use as a pre-reactive group. Clavulanic acid (CA) is an approved β-lactam 
antibiotic that inhibits bacterial β-lactamases. CA was originally discovered as a 
product of Streptomyces clavuligerus in 1976 [96], and has found widespread use in 
combination with other traditional β-lactam antibiotics, commonly Amoxicillin, to treat 
both Gram-positive and Gram-negative infections [97]. CA is a suitable candidate for 
use as a pre-reactive group particular due to its two-step mechanism (Figure 20). 
Experimental data support that upon initial binding of CA to the active site of its natural 
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target β-lactamase, CA acylates a serine residue causing the lactam ring to open, and 
yielding an imminium intermediate [96]. Tautomerization of the imminium intermediate 
to an enamine intermediate enables acylation of an additional serine residue, resulting 
in a cross-linked β-lactamase. To adapt CA for use as a pre-reactive group, we 
proposed to use a nucleophilic pre-reactive group pair that can function similarly to the 
initial β-lactamase serine residue, reacting with CA to reveal a reactive intermediate 
that subsequently acylates an amino acid side chain in the active site of RT. An ideal 
pre-reactive group pair for CA is 2,3,5,6-Tetrafluoro-4-hydroxy-benzoic acid (TF) due 
to its pKa, predicted to be 6.4 for the key oxygen atom attached to the 4
th position of 
the benzylic ring. (Calculated using ChemAxon MarvinSketch). Thus, at cytosolic pH, 
typically above 7 [98], approximately 80% of TF would be deprotonated and could be 
acylated by CA if the two pre-reactive groups were in proximity. Importantly, these two 
pre-reactive groups were also selected since they contained carboxylic acid groups 
that could be used to attach these groups to dTTP through standard synthetic 
procedures [99-102]. The structures of CA and TF analgos of dTTP are shown in 
Figure 21. 
The CA-TF binary reagent inhibited RT activity. CA and TF were incorporated 
into a primer with a template  that allowed incorporation of only one TF or CA in order 
to simulate the use of chain terminating dideoxynucleotides (ddNTP) that would cause 
chain termination. Alone, both analogs had minimal effect on RT activity. However, in 
the presence of both analogs the RT activity was reduced significantly (Figure 22 and 
23A). In an effort to confirm the covalent mechanism, we tested the effect of 
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incubation time on RT inactivation. The effect of a covalent inhibitor can vary in 
experiments with different incubation times due to the requisite time for the covalent 
bond to form. A challenge which disallows the use of more traditional characterization 
of an inhibitors effect on a target enzyme [77]. Surprisingly, incubation time had little 
effect on the potency of the CA-TF binary reagent, under our experimental conditions 
(Figure 22). In effort to further characterize the nature of the CA-TF binary reagent, we 
used a molecular beacon RT activity assay that allows real time monitoring (Figure18). 
These experiments confirmed the gel analysis, showing that CA-TF inhibited RT 
(Figure 22). However, TF alone also significantly inhibited RT activity, likely due to the 
much higher ratio of TF to primer/template in this assay compared to the gel analysis. 
Interestingly, after 30 minutes an additional aliquot of the primer and MB probe were 
added, and the sample containing both CA and TF failed to produce any increase in 
fluorescent signal in the subsequent 30 minutes (Figure 23A). This result suggests 
that the CA-TF binary reagent may indeed covalently inhibit RT. Next, to compare the 
CA-TF binary reagent to traditional NRTIs we used commercially available 
triphosphate of ziduvudine (AZT) in the same assay. In order to inhibit RT at the same 
level as CA-TF during the first thirty minutes of the experiment, 10X the concentration 
of AZT (100 μM) compared to total CA and TF was required (Figure 23B). Importantly, 
after the second addition of primer and MB probe, even this sample showed an 
increase in fluorescent intensity, indicated remaining RT activity. This was expected 
since AZT does not covalently inhibit RT, and this result illustrates the potential utility 
of a covalent mechanism of action. 
51 
Despite these promising results using the CA-TF pair, additional pre-reactive 
group pairs were explored due to difficulties with CA analog synthesis. Indeed, even 
commercial efforts to produce CA for use as an antibiotic have been plagued by the 
poor stability of this compound [97]. Our characterization failed to reliably determine 
whether the compounds used in this study contained the complete clavulanic acid ring 
or a decomposition product (data not shown). Fortunately, a related β-lactam 
compound, sulbactam, showed improved stability [103,104], but still offers a similar 
mechanism that is amenable to adaption for the development of a covalent inhibitor 
using the binary approach.  
Sulbactam(SB)-TF pre-reactive group pair 
Sulbactam (SB) was originally designed and synthesized as an alternative for 
clavulanic acid [105], and displayed lower reactivity but higher stability. Importantly, 
similar to CA, SB is predicted to inhibit β-lactamases through a two-step mechanism 
making SB an attractive option as a pre-reactive group (Figure 24) [106]. Additionally, 
SB also contains a carboxylic acid that was used for attachment to dTTP (Figure 21). 
The structure of the SB dTTP analog is shown in Figure 21. Since SB has a similar 
mechanism as CA, TF is an ideal pre-reactive group partner.  
The SB analog of dTTP alone had little effect on RT activity at low 
concentrations (Figure 25). However, in the presence of both SB and TF, RT was 
significantly inhibited. Interestingly, the potency was greater when TF was the first 
analog added. Unfortunately, thorough characterization of SB analogs was plagued by 
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similar setbacks as CA. However, the data presented herein provides an impetus for 
more synthetic efforts as both SB and CA or their degradation products show 
promising characteristics as pre-reactive groups in a covalent inhibitor designed by 
following the binary approach. In order to explore the conformation of the SB and TF 
pre-reactive groups in the RT active site and to aid in the design of future binary 
inhibitors we performed molecular dynamics simulations.   
Molecular dynamics (MD) of Sulbactam-TF binary reagent 
MD simulations of various combinations of SB-TF binary reagent components 
were performed in order to sample the conformations of the pre-reactive groups in the 
active site of RT. Furthermore, MD simulations allowed us to sample the distances 
between the pre-reactive groups and RT amino acids. We also sought any evidence to 
explain the improved potency of TF-SB reagent when TF is incorporated into the 
primer. The protein database structure 1RTD [83] was used as a template to build 
structures for MD simulations. This structure contains the full RT heterodimer in a 
ternary complex with a DNA primer-template and an incoming ddTTP bound in the 
nucleotide-binding site (Figure 17). Thus, we built four different structures based on 
this template. Each structure contained different dTTP or dTTP analogs in the 3’end of 
the primer or in the nucleotide-binding site (Figure 17C yellow and green). As a 
control, we used RT in complex with dTTP bound in the nucleotide-binding site (Figure 
26A). In the second structure SBdTTP was bound to the nucleotide-binding site 
(Figure 26B). The third structure contained SBdTMP incorporated into the primer and 
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TFdTTP bound to the nucleotide-binding site (Figure 26C). The fourth structure had 
TFdTMP incorporated into the primer and SBdTTP bound to the nucleotide-binding 
site (Figure 26D). All four structures were prepped in the same way, and MD 
production for each was collected (Table 3). 
To assess the stability of each structure throughout the MD simulation, the root 
mean square deviation (RMSD) was calculated. RMSD measures the difference in the 
location of atoms throughout the trajectory. Thus, a low RMSD indicates a stable 
structure, as the atoms are not deviating away from there original position. RMSD 
values were calculated for the entire MD production trajectory in four different ways for 
each structure. First, the entire system compared to the initial structure prior to MD 
production. Second, the protein backbone compared to the initial structure prior to MD 
production. Third, the DNA compared to initial structure prior to MD production. 
Fourth, the protein backbone compared to the original 1RTD crystal structure. All four 
structures were remarkably stable, with average RMSD values below 3 Å (Figure 27). 
To ascertain whether any favorable conformations between the pre-reactive 
groups and protein amino acids were formed during MD simulation, the distance 
between various groups throughout the trajectories were measured. Interestingly, the 
average distance between TF and SB in the SBdTMP-TFdTTP structure is greater 
than 10Å (Figure 28). However, in the TFdTMP-SBdTTP structure, that same 
combination which inhibited RT activity, the average distance is less than 10 Å. 
Furthermore, in the TFdTMP-SBdTTP structure, the TF forms a stable interaction with 
Lys66 due to the negative charge on the TF oxygen and positively charged lysine side 
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chain. This structural conformation indicates a mechanism in which TF deprotonates 
Lys66, which is located in a flexible loop (Figure26 green loop), allowing it to react with 
SB bound in the nucleotide-binding site. Over all, the MD simulations support our 
finding that TFdTMP-SBdTTP is more potent inhibitor of RT, due to the distances 
between these critical residues and offers a potential mechanism worth expiring in 
future studies.  
Discussion 
Chemical probes that covalently modify their target are extremely useful as 
research tools and for drug design strategies [77,107]. Using the binary approach to 
make covalent chemical probes offers selective control over the generation of the 
reactive portion of the probe. Herein, the binary approach was applied to the design of 
covalent inhibitors for RT, which we establish as a model for testing of future pre-
reactive group pairs. The CA/SB-TF pre-reactive group pair was investigated and 
shows promise as an ideal candidate for future use in binary reagents. This particular 
reagent was explored using MD simulations to confirm possible confirmations that 
would allow the pre-reactive groups to react with amino acids RT. This work also 
creates a system to test other another important component of the binary approach 
that can be optimized: the linker arm between the ligand and the pre-reactive group. 
An allylamine linker arm was used in this study, and due to conjugation with the 
thymidine ring, and limited rotatable bonds, only minor conformational changes were 
observed during MD simulation. Future study of similar systems with more flexible 
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linkers may reveal more favorable confirmations between the pre-reactive groups and 
amino acid side chains on RT or other targets. In addition to new linker arms, efforts to 
create robust synthetic procedures and thorough characterization of SB and CA 
analogs will enable full characterization of the mechanism by which these reagents 
inhibit RT. CA or SB might become a general pair of reagents that can easily be 
conjugated to ligands for other targets to quickly generate a robust and selective 
chemical probe.    
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Figures and tables 
 
Figure 17. HIV-1 reverse transcriptase is an excellent binary approach model 
target. 
A) Front surface rendering of HIV-1 RT [83]. Dark grey shows p51 subunit. The p66 subunit is 
composed of the RNaseH domain (light grey), fingers (green), palm (yellow), and thumb (orange) 
domains. A Primer (red) and template (blue) is bound to RT situating the 3’-end of the primer near 
the polymerase active site located in the palm region. 
B) Side view of RT. 
C) Top view of RT; insert shows close up of polymerase active site. The nucleotide binding site and 
primer 3’-end sites are adjacent, as required for use of the binary approach. Importantly, at least 
one lysine is located nearby (8 angstroms) which may react with products of binary reagents. 
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Figure 18. Molecular beacon (MB) assay for real time monitoring of HIV RT 
activity. 
A) Sequence of MB probe (black) and primer (orange). The primer was designed so the 3’ end would 
be adjacent to an adenine in the template to ensure that a dTTP analog would be encorporated. 
B) Fluorescent intensity of MB probe in the absence or presence of RT and primer. 
58 
 









Figure 21. CA, SB, and TF dTTP analog structures. 
Clavulanic acid (CA), sulbactam (SB), and 2,3,5,6-tetrafluoro-4-hydroxy benzoic acid (TF) analogs of 
dTTP were synthesized by acylating the amine group of the allyamine linker with N-hydroxysuccinimide 
esters of each pre-reactive group, as previously described [99,101,102]. Green in dTTP structure 







Figure 22. CA-TF Binary Reagent Inhibits RT. 
A) Gel analysis of RT activity. Samples contents are indicated by color in part B. 





Figure 23. Comparison between binary reagent CA-TF and NRTI AZT. 
A) CA-TF covalent inhibitor inactivates RT. During the first 30 minute incubation the CA-TF reagent 
inhibits RT activity aproximatley 50%. However, after addition of another aliquot of MB and primer 
at 30 minutes, the RT shows no activity in the CA-TF sample, indicating inactivation 
B) AZT inhibits RT, yet even at concentration 10X higher than used for the CA-TF binary reagent, RT 















Figure 26. Active sites of RT structures used in MD study. 
A) dTTP: RT structure with dTTP bound to the nucleotide binding site.   
B) SBdTTP. RT structure with dTTP bound to the nucleotide binding site. 
C) SBdTMP_TFdTTP: RT structure with SBdTMP at the 3’end of the primer and TFdTTP bound to the 
nucleotide binding site. 
D) TFdTMP_SBdTTP RT structure with TFdTMP at the 3’end of the primer and SBdTTP bound to the 





Table 3. RT structures and production time from Molecular Dyanmics 
Simulations 
RT Structure Production Time 
dTTP 8.8 ns 
SBdTTP 14.6 ns  
SBdTMP_TFdTTP 12.5 ns 






Figure 27. RMSD values for MD simulations. 
The protein backbone or DNA (top right only) of all structures was aligned and RMSD values were 
calculated using VMD RMSD trajectory tool by comparing each frame of MD simulation trajectory data 
to either the initial structure prior to production or to the original crystal structure from the protein 




Figure 28. Distance between pre-reactive groups and RT lysine residues. 
In three of the MD structures, the distance between pre-reactive groups and RT lysine residues were 
calculated through the entire trajectory. Measurements of SB were from the carbonyl carbon in the β-
lactam ring. TF was measured from the terminal oxygen. Lysine residues were measured from the 
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